Loading company…
Proviva Therapeutics develops cytokine-based biologics and platforms for cancer treatment.
Founded in 2019, Shanghai-based Proviva Therapeutics develops cytokine-based antitumor biologics using its Crossover prodrug and MUSICA immune-activation platforms. Its candidates include PTX-912, and its research also addresses infectious diseases. The company is a subsidiary of Viva Biotech Holdings and closed a Series A+ round in December 2025, led by OrbiMed Advisors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in